Promega cancer treatment screening test expected to expand company
A genetic test developed by Promega Corp. could help doctors decide which patients get a widely used cancer drug, following a collaboration announced Wednesday by Promega and drug maker Merck.

The development, pending federal approval, is expected to propel Promega’s growth and account for 10% to 20% of the company’s business in five years, Promega CEO Bill Linton said. Promega has 1,682 employees, including 1,055 at its Fitchburg headquarters.

“It’s something that we think is transformational in the field of human therapy and specifically cancer therapies,” Linton said.


Ken Notes: Madison could become the World hub for genetic testing!

- - Volume: 7 - WEEK: 45 Date: 11/7/2019 7:47:34 AM -